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Endovascular therapy in patients with large 
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Abstract
Background and aims: To investigate whether stroke aetiology affects outcome in patients 
with acute ischaemic stroke who undergo endovascular therapy.
Methods: We retrospectively analysed patients from the Bernese Stroke Centre Registry 
(January 2010–September 2018), with acute large vessel occlusion in the anterior circulation 
due to cardioembolism or large-artery atherosclerosis, treated with endovascular therapy 
(±intravenous thrombolysis).
Results: The study included 850 patients (median age 77.4 years, 49.3% female, 80.1% 
with cardioembolism). Compared with those with large-artery atherosclerosis, patients 
with cardioembolism were older, more often female, and more likely to have a history of 
hypercholesterolaemia, atrial fibrillation, current smoking (each p < 0.0001) and higher 
median National Institutes of Health Stroke Scale (NIHSS) scores on admission (p = 0.030). 
They were more frequently treated with stent retrievers (p = 0.007), but the median number 
of stent retriever attempts was lower (p = 0.016) and fewer had permanent stent placements 
(p ⩽ 0.004). Univariable analysis showed that patients with cardioembolism had worse 3-month 
survival [72.7% versus 84%, odds ratio (OR) = 0.51; p = 0.004] and modified Rankin scale (mRS) 
score shift (p = 0.043) and higher rates of post-interventional heart failure (33.5% versus 18.5%, 
OR = 2.22; p < 0.0001), but better modified thrombolysis in cerebral infarction (mTICI) score 
shift (p = 0.025). Excellent (mRS = 0–1) 3-month outcome, successful reperfusion (mTICI = 2b–3), 
symptomatic intracranial haemorrhage and Updated Charlson Comorbidity Index were similar 
between groups. Propensity-matched analysis found no statistically significant difference 
in outcome between stroke aetiology groups. Stroke aetiology was not an independent 
predictor of favourable mRS score shift, but lower admission NIHSS score, younger age and 
independence pre-stroke were (each p < 0.0001). Stroke aetiology was not an independent 
predictor of heart failure, but older age, admission antithrombotics and dependence pre-
stroke were (each ⩽0.027). Stroke aetiology was not an independent predictor of favourable 
mTICI score shift, but application of stent retriever and no permanent intracranial stent 
placement were (each ⩽0.044).
Conclusion: We suggest prospective studies to further elucidate differences in reperfusion 
and outcome between patients with cardioembolism and large-artery atherosclerosis.
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Introduction
In patients with acute ischaemic stroke, the 
immediate aim is to restore blood flow to salvage-
able brain tissue. The long-term aim is to improve 
outcome by reducing disability and mortality. 
Effective options for reperfusion therapy are 
intravenous alteplase, intravenous tenecteplase 
and endovascular therapy (±intravenous throm-
bolysis). Endovascular therapy (±intravenous 
thrombolysis) has the potential to improve 
3-month outcome in patients with acute ischae-
mic stroke and large vessel occlusion in the ante-
rior circulation if they have no contraindications 
and can be treated within a few hours of stroke 
onset.1,2
Two of the most common stroke aetiologies 
involve cardioembolism and large-artery athero-
sclerosis.3,4 Large-artery atherosclerosis is typified 
by a significant narrowing of extra- or intracranial 
brain-supplying arteries, potentially leading to 
local vessel occlusion, embolism and/or, less fre-
quently, to haemodynamic impairment.3,4 
Investigation of stroke aetiology is requisite for tar-
geted secondary prevention to reduce recurrence 
and may support improved outcome in dedicated 
stroke units.5,6 Vascular risk factor profiles and 
other data have been shown to differ between the 
two stroke aetiologies mentioned above, with acute 
ischaemic stroke of cardioembolic origin histori-
cally being associated with worse outcome.7–9 
Stroke aetiology might influence the outcome of 
reperfusion.10,11 However, data on endovascular 
therapy (±intravenous thrombolysis) that include 
comparison of stroke aetiology are scarce.9,11–13
The aim of this study was to compare patients 
with cardioembolism versus large-artery athero-
sclerosis as determined stroke aetiology and to 
investigate whether stroke aetiology has an impact 
on reperfusion and outcome in patients with 
acute ischaemic stroke and large vessel occlusion 
in anterior circulation treated with endovascular 
therapy, including intra-arterial thrombolysis 




The study patients were from the Bernese Stroke 
Registry, a prospectively collected database, 
which has been described previously.14,15 Patients 
were included in this analysis if they had suffered 
an acute ischaemic stroke in the anterior circula-
tion [with a vessel occlusion location in at least 
one of the following segments: extra- or intracra-
nial internal carotid artery (ICA), ICA-T or M1- 
or M2-segment of the middle cerebral artery 
(MCA)] between January 2010 and September 
2018. Only patients who had endovascular ther-
apy, including intra-arterial thrombolysis and/or 
mechanical thrombectomy (±intravenous throm-
bolysis) were eligible. Baseline characteristics and 
demographic data were recorded. Clinical assess-
ment was performed by a certified stroke neurolo-
gist on admission using the 15-item version of the 
National Institutes of Health Stroke Scale 
(NIHSS) score.16 Patients underwent computed 
tomography angiography (CTA) and/or magnetic 
resonance angiography (MRA) to confirm acute 
ischaemic lesions and the site of acute vessel 
occlusion. All images were reviewed retrospec-
tively by a board-certified stroke neurologist 
(MRH) and an interventional neuroradiologist 
(EIP), blinded to clinical findings. CTAs were 
acquired with a 64- or 128-slice multidetector-
row CT scanner (Somatom Definition AS and 
Somatom Definition Edge; Siemens, Erlangen, 
Germany) with the patient in a head-first posi-
tion, 1.5-s gantry rotation time, 0.6-mm collima-
tion and a pitch of 1.2, 512 × 512 matrix size 
automatic exposure control (CARE Dose 4D; 
Siemens Healthcare, Forchheim, Germany) and 
automatically adjusted radiation output accord-
ing to patient morphology. Forty millilitres of 
Iomeron® 400 (Bracco, Cadempino, Switzerland) 
was administered intravenously. Contrast-
enhanced MRA of the neck and intracranial ves-
sels and time-of-flight MRA of the intracranial 
arteries were acquired on a 1.5T or 3T MR scan-
ner (Magnetom Avanto and Magnetom Verio; 
Siemens, Erlangen, Germany). The MR protocol 
included whole brain diffusion-weighted imaging 
[b = 1000t, 24 slices, thickness 5 mm, repetition 
time (TR) 3200 ms, echo time (TE) 87 ms, num-
ber of averages 2, matrix 256 × 256] yielding iso-
tropic b0 and b1000 and time-of-flight 
angiography with the following parameters: 1.5 
T: TR, 23 ms; TE, 7 ms; number of averages, 1; 
field of view (FOV) read, 180 mm; FOV phase, 
100%; voxel size, 0.9 × 0.7 × 1.2 mm; flip angle, 
25°; acquisition time, 3 min 28 s/3T: TR, 22 ms; 
TE, 3.6 ms; number of averages, 1; FOV read, 
180 mm; FOV phase, 100%; voxel size, 
0.6 mm × 0.4 mm × 1.2 mm; flip angle, 20°; 
acquisition time, 3 min 45 s. After CT and/or MR 
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imaging, digital subtraction angiography (DSA) 
was performed on a biplane, high-resolution angi-
ographic system (Axiom Artis zee and Axiom 
Artis Q; Siemens, Erlangen, Germany) using 
Iopamiro® 300 (Iopamidol, Bracco, Switzerland) 
as contrast agent.
Acute stroke treatment with endovascular therapy 
including intra-arterial thrombolysis and/or 
mechanical thrombectomy (±intravenous throm-
bolysis) was performed according to international 
and institutional guidelines.1 Our institutional 
protocol included intra-arterial thrombolysis with 
urokinase (Medac GmbH and Opopharma 
Vertriebs AG), injected manually before or next 
to and distal to the thrombus, in dosages of up to 
1,000,000 IU, in lower dosages in the case of pre-
interventional intravenous thrombolysis.17 Our 
institutional protocol did not include tenecteplase 
for intravenous thrombolysis.
The decision to perform endovascular therapy 
was made on an individual basis, by a consensus 
between the treating neurologist and neuroradi-
ologist and was independent of this study. 
Possible contraindications were considered in 
accordance with current institutional and interna-
tional guidelines. Eligibility for intravenous 
thrombolysis was based on the time lapse from 
symptom onset (<4.5 h) or in recent years also 
based on last time seen well [inclusion if diffu-
sion-weighted MR imaging and T2-weighted 
and/or fluid-attenuated inversion recovery 
(FLAIR) imaging mismatch and no clear and/or 
extensive hyperintensity, or if no area of hypoat-
tenuation in CT imaging]. If feasible, endovascu-
lar therapy proceeded as follows: approaching/
passing the thrombi with a microwire, application 
of angioplasty balloon catheters, clot aspiration 
and/or application of retrievable stents and, if 
needed, permanent stent placements.
After treatment for acute stroke, patients were 
intensively monitored in the stroke unit, interme-
diate or intensive care unit if deemed necessary. 
Besides neuroimaging, a standard investigation of 
stroke aetiology was performed according to 
international and local guidelines. This included 
laboratory analysis, 12-lead electrocardiogram, 
7-day electrocardiogram (repeated twice more in 
the following weeks), transoesophageal and/or 
transthoracic echocardiography and neurovascu-
lar sonography.1 Stroke aetiology was determined 
using a slightly modified TOAST classification.1 
Only patients whose stroke aetiology was deter-
mined to be cardioembolism or large-artery ath-
erosclerosis were included in this study.3,4 
Presence, location and degree of large-artery ath-
erosclerosis were diagnosed in serial digital sub-
traction angiography images and confirmed in 
CTA and/or MRA. Patients with atrial fibrillation 
were included in the large-artery atherosclerosis 
group, if neuroimaging revealed large-artery ath-
erosclerosis and multiple/multi-stage ischaemic 
lesions in a single ICA territory and plaque neuro-
imaging, history and other investigations further 
supported this classification.
Follow-up CTA/MRA were performed 12–24 h 
after acute stroke treatment and/or earlier in cases 
of secondary neurological deterioration. Clinical 
follow-up was done face-to-face by a certified 
neurologist or in a telephone interview by a 
trained study nurse at 3 months. Clinical outcome 
was measured with the post-interventional 
Updated Charlson Comorbidity Index, NIHSS 
score at discharge, change in NIHSS score (score 
at discharge minus score at admission), 3-month 
modified Rankin scale (mRS) score (excellent 
outcome = mRS 0–1; favourable outcome = mRS 
0–2; survival = mRS 0–5), scored by a certified 
stroke neurologist.18,19 Imaging outcome meas-
ures were: successful reperfusion [modified 
thrombolysis in cerebral infarction (mTICI) 2b–3] 
immediately after DSA, final in-hospital infarct 
volume (measured semi-quantitatively by manual 
outlining in T2 or FLAIR MR and/or CT imag-
ing, by multiplication of total area in single slices 
multiplied by slice thickness) and symptomatic 
intracranial haemorrhage (sICH) during follow-
up, defined according to the ECASS III study.20,21
Statistical analysis
Statistical analysis was performed using SPSS 25.0 
(SPSS Inc., Chicago, Illinois, USA). Baseline 
characteristics, demographic data, vascular risk 
factors, baseline imaging findings, treatment 
details and outcome variables were compared 
between patients with cardioembolism versus large-
artery atherosclerosis using the χ2-test for categori-
cal variables and Fisher’s exact test if appropriate, 
and the non-parametric median test for continu-
ous and ordinal variables. Outcome parameters 
were dichotomized into excellent (mRS 0–1 versus 
2–6) and favourable (mRS 0–2 versus 3–6) out-
come; survival (mRS 0–5 versus 6) at 3 months; 
successful reperfusion (mTICI 2b–3 versus 0–2a), 
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heart failure (yes versus no) and sICH (yes versus 
no). These binary outcome variables, stratified 
according to both stroke aetiology and successful 
reperfusion, were subjected to univariable logistic 
regression analysis. mRS, mTICI, Updated 
Charlson Comorbidity Index and final in-hospital 
infarct volume were subjected to ordinal regression 
analysis (shift analysis). Ordinal and multivariable 
logistic regression analysis was applied to identify 
independent predictors of a mRS and mTICI shift 
and of heart failure and sICH (variables entered 
included baseline characteristics, demographic 
data and treatment details with a p < 0.100 in uni-
variable analysis). We also did a sensitivity analysis 
of patients who had a high-grade stenosis (accord-
ing to NASCET and SAMMPRIS criteria) prior 
to large vessel occlusion.22,23
A propensity-matched analysis (in one analysis 
the variables entered included baseline character-
istics and demographic data and in the other 
treatment details as well, if a p < 0.100 had been 
obtained in univariable analysis) was performed 




Between January 2010 and September 2018, 2704 
patients with acute stroke were treated with 
 endovascular therapy or intravenous thrombolysis 
at the Bernese stroke centre. Of these patients, 
1705 underwent endovascular therapy including 
intra-arterial thrombolysis and/or mechanical 
thrombectomy (±intravenous thrombolysis). In 
681 patients with acute ischaemic stroke in the 
anterior circulation, cardioembolism was deter-
mined to be the stroke aetiology whereas large-
artery atherosclerosis was diagnosed in 169 patients 
(in 13% of patients in intracranial location). This 
resulted in a total of 850 patients (median age 
77.4 years, 49.3% female) eligible for inclusion in 
this study (Figure 1). Differences in baseline char-
acteristics, demographic data and in treatment 
details were noted between groups. Patients with 
cardioembolism versus large-artery atherosclerosis 
were older (p < 0.0001), more frequently female 
(p < 0.0001), more likely to have a history of hyper-
cholesterolaemia (p < 0.0001), atrial fibrillation 
(p < 0.0001), current smoking (p < 0.0001) and a 
higher median NIHSS score on admission 
(p = 0.030). Also, they were more likely to have suf-
fered a previous acute ischaemic stroke (p = 0.056) 
and to have been less independent (p = 0.063) than 
patients with large-artery atherosclerosis pre-stroke. 
Time delays from symptom onset to admission 
(p = 0.688) as well as to endovascular therapy 
(±intravenous thrombolysis) (p = 0.375), location 
of acute large vessel occlusion (p = 0.163) and ther-
apy modality applied (p = 0.274) were similar in 
both stroke aetiology groups. A stent retriever was 
more often used in patients with cardioembolism 
(p = 0.007), but the median number of stent 
retriever attempts was lower (1 versus 2, p = 0.016) 
and they had fewer permanent extra- (p < 0.0001) 
as well as fewer intracranial (p = 0.004) stent 
 placements than patients with large-artery athero-
sclerosis (Table 1).
Figure 1. Flow chart of patient selection.
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Age, median years (range) 78.8 (18–98) 71.2 (48–94) 0.0001
Women 365 (53.6%) 54 (32%) 0.0001
Vascular risk factors
 Arterial hypertension 519 (76.4%) 124 (73.4%) 0.405
 Diabetes mellitus 116 (17.2%) 37 (22%) 0.143
 Hypercholesterolaemia 338 (50.4%) 121 (73.3%) 0.0001
 Atrial fibrillation 503 (75%) 14 (8.9%) 0.0001
 Current smoking 87 (12.9%) 56 (33.3%) 0.0001
 Coronary heart disease 175 (26%) 34 (20.1%) 0.111
 Previous stroke 98 (14.5%) 15 (8.9%) 0.056
Independent (mRS 0–2) pre-stroke 587 (87.7%) 155 (92.8%) 0.063
Time delays, median minutes (range)
 From symptom onset to admission 144 (0–1413) 161 (0–1314) 0.688
 From symptom onset to EVT 233 (13–1436) 243 (37–1409) 0.375
Admission NIHSS score, median (range) 15 (0–38) 13 (1–28) 0.030
Admission antithrombotics 384 (56.7%) 65 (38.5%) 0.0001
Location of acute large vessel occlusion 0.163
 Extracranial ICA 5 (0.7%) 6 (3.6%)  
 Intracranial ICA 33 (4.8%) 8 (4.7%)  
 ICA-T (±extracranial ICA) 35 (5.1%) 10 (5.9%)  
 ICA and A1 tandem 4 (0.6%) 1 (0.6%)  
 M1 segment (±ICA) 436 (64%) 107 (63.3%)  
 M2 segment (±ICA) 144 (21.1%) 33 (19.5%)  
 M1 or M2 segment and A1 segment 4 (0.6%) 4 (2.4%)  
Therapy modality 0.274
 IA-urokinase 33 (4.8%) 5 (3%)  
 Mechanical thrombectomy† 347 (51%) 86 (50.9%)  
 IA-urokinase and mechanical thrombectomy† 49 (7.2%) 7 (4.1%)  
 IVT and EVT 252 (37%) 71 (42%)  
(Continued)









 Local 37 (5.4%) 7 (4.1%)  
 Conscious sedation 203 (29.8%) 25 (14.8%)  
 General 441 (64.8%) 137 (81.1%)  
Time from groin puncture to end of EVT, median minutes (range) 54 (9–360) 90 (18–239) 0.0001
Application of stent retriever 579 (85%) 129 (76.3%) 0.007
Number of stent retriever attempts, median (range) 1 (1–8) 2 (1–6) 0.016
Permanent stenting
 Extracranial 19 (2.8%) 107 (63.3%) 0.0001
 Intracranial 13 (1.9%) 10 (5.9%) 0.004
Values are presented as number (%) unless otherwise specified. Percentages indicate available data. Missing data were considered as missing, as 
they were incidentally missing.
*p-values compare both groups.
†Either clot aspiration and/or application of retrievable stents.
EVT, endovascular therapy; ICA, internal carotid artery; IVT, intravenous thrombolysis; mRS, modified Rankin scale; NIHSS, National Institutes of 
Health Stroke Scale.
Table 1. (Continued)
Univariable analysis showed that likelihood of 
excellent outcome at 3 months was comparable 
between the two stroke aetiology groups 
(p = 0.642). Patients with cardioembolism versus 
large-artery atherosclerosis showed a tendency 
towards less favourable 3-month outcome [40.6% 
versus 48.8%, odds ratio (OR) = 0.72, p = 0.059] 
and poorer 3-month survival (72.7% versus 84%, 
OR 0.51, p = 0.004) and more post-interventional 
heart failure (33% versus 18.5%, OR 2.17, 
p < 0.0001). There was a smaller shift towards 
lower 3-month mRS scores for patients with car-
dioembolism (p = 0.043), but a larger shift 
towards better mTICI scores after endovascular 
therapy (p = 0.025; Figure 2). Successful reperfu-
sion (p = 0.168) and sICH (p = 0.683) did not dif-
fer between the two stroke aetiology groups 
(Table 2).
Patients with cardioembolism
Univariable analysis also showed that excellent out-
come at 3 months was similar in patients with car-
dioembolism and with successful versus unsuccessful 
reperfusion (p = 0.277). Favourable 3-month out-
come (43.8% versus 27.7%, OR 2.04, p = 0.001) 
and 3-month survival (75.6% versus 61.1%, OR 
1.97, p = 0.001) were more often seen in patients 
with successful versus unsuccessful reperfusion. The 
same patients also showed a larger shift towards 
lower 3-month mRS scores and post- interventional 
Updated Charlson Comorbidity Indexes (each 
p < 0.0001). sICH occurred in 4.5% patients 
with cardioembolism and successful  reperfusion 
and in 5.2% patients with unsuccessful reperfusion 
(p = 0.707) (Table 3).
Figure 2. Successful reperfusion according to stroke aetiology.
mTICI, modified thrombolysis in cerebral infarction.
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Patients with large-artery atherosclerosis
Excellent 3-month outcome was similar in 
patients with large-artery atherosclerosis 
whether or not reperfusion was successful 
(p = 0.120). There was a tendency towards more 
favourable 3-month outcome (mRS 0–2) 
(p = 0.081) in patients with large-artery athero-
sclerosis who had successful reperfusion. 
Survival at 3 months (p = 0.499) did not differ 
between the two reperfusion groups. Patients 
with successful reperfusion showed a tendency 
towards a better shift of lower 3-months mRS 
scores (p = 0.083). sICH occurred in 5.6% 
patients with large-artery atherosclerosis who 
had successful reperfusion and in 4.9% patients 
in whom reperfusion was unsuccessful 
(p = 0.868) (Table 3). In the subgroup analysis 
of patients who had a high-grade stenosis prior 
to large vessel occlusion, outcomes were similar 
in both reperfusion groups (Table 3).
Patients in propensity-matched analysis
In propensity-matched analysis there was no 
 difference in group comparisons, only, there was 
a tendency towards a lower median NIHSS score 
at discharge in patients with cardioembolism 
(4 versus 7, p = 0.076) not matched to the patients 
with large-artery atherosclerosis for therapy 
details (Tables 4 and 5).
Stroke aetiology as predictor of outcome
Stroke aetiology was neither an independent 
 predictor of favourable mRS score shift, but lower 
admission NIHSS score, younger age and inde-
pendence pre-stroke (each p < 0.0001), nor of 
heart failure, but older age, admission antithrom-
botics and dependence pre-stroke (each ⩽0.027), 
nor of favourable mTICI score shift, but  application 
of stent retriever and no permanent intracranial 
stent placement (each ⩽0.044). Neither stroke 




athero sclerosis  
group* n = 168




mRS at 3 months 0.043‡
 0–1 127 (19.5%) 29 (17.9%) 0.642 1.11 (0.71–1.74)  
 0–2 264 (40.6%) 79 (48.8%) 0.059 0.72 (0.51–1.01)  
 0–5 (survival) 474 (72.7%) 136 (84%) 0.004 0.51 (0.32–0.80)  
 Median, range 3, 0–6 3, 0–6 0.133  
Successful reperfusion 
(mTICI 2b–3)




 Median, range 3, 0–16 2, 0–12 0.479  
 Subitem heart failure 215 (33%) 30 (18.5%) <0.0001 2.17 (1.41–3.43)  
Symptomatic intracranial 
haemorrhage
31 (4.6%) 9 (5.4%) 0.683 0.85 (0.40–1.83) NA
Values are presented as number (%). Percentages indicate available data. Missing data were considered as missing, as they were incidentally 
missing.
*Denominator.
†Values compare both groups.
‡Shift over the whole spectrum of the score.
CI, confidence interval; mRS, modified Rankin scale; mTICI, modified thrombolysis in cerebral infarction.
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Table 3. Outcome according to reperfusion.










mRS at 3 months <0.0001‡
 0–1 106 (20.4%) 21 (16.2%) 0.278 1.33 (0.80–2.22)  
 0–2 228 (43.8%) 36 (27.7%) 0.001 2.04 (1.34–3.11)  
 0–5 (survival) 393 (75.6%) 80 (61.1%) 0.001 1.97 (1.32–2.96)  
 Median, range 3, 0–6 4, 0–6 <0.0001  
Updated Charlson Comorbidity Index <0.0001‡
 Median, range 2, 0–16 4, 0–13 <0.0001  
 Subitem heart failure 162 (31.2%) 52 (40%) 0.056 0.70 (0.46–1.01)  
Symptomatic intracranial haemorrhage 24 (4.5%) 7 (5.2%) 0.707 0.85 (0.36–2.01) NA






group* n = 41




mRS at 3 months 0.083‡
 0–1 25 (20.8%) 4 (9.8%) 0.120 2.43 (0.79–7.47)  
 0–2 63 (52.5%) 15 (36.6%) 0.081 1.92 (0.92–3.97)  
 0–5 (survival) 102 (85%) 33 (80.5%) 0.499 1.37 (0.55–3.45)  
 Median, range 2, 0–6 3, 0–6 0.093  
Updated Charlson Comorbidity Index 0.503‡
 Median, range 2, 0–12 4, 0–9 0.534  
 Subitem heart failure 21 (17.5%) 9 (22%) 0.528 0.75 (0.31–1.81)  
Symptomatic intracranial haemorrhage 7 (5.6%) 2 (4.9%) 0.868 1.15 (0.23–5.75) NA
Large-artery atherosclerosis group  





group* n = 24




mRS at 3 months 0.523‡
 0–1 14 (21.5%) 3 (12.5%) 0.342 1.92 (0.50–7.39)  
 0–2 29 (44.6%) 11 (45.8%) 0.918 0.95 (0.37–2.44)  
 0–5 (survival) 56 (86.2%) 19 (79.2%) 0.422 1.64 (0.49–5.50)  
 Median, range 3, 0–6 3, 0–6 0.766  
Updated Charlson Comorbidity Index 0.806‡
 Median, range 2, 0–12 2, 0–9 0.826  
 Subitem heart failure 10 (15.4%) 5 (20.8%) 0.544 0.69 (0.21–2.28)  
Symptomatic intracranial haemorrhage 4 (5.8%) 1 (4%) 0.733 1.48 (0.16–13.88) NA
Values are presented as number (%). Percentages indicate available data. Missing data were considered as missing, as they were incidentally missing.
*Denominator.
†Values compare both groups.
‡Shift over the whole spectrum of the score.
CI, confidence interval; mRS, Modified Rankin scale; NA, not applicable.
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aetiology nor the other variables entered into the 
model were independent predictors of sICH 
(Table 6).
Discussion
The main findings of our study were as follows: 
univariable analysis showed that 3-month out-
come was similar between patients with cardioem-
bolism and those with large-artery atherosclerosis, 
despite a better reperfusion shift in patients with 
cardioembolism. However, in patients within the 
cardioembolism-group, successful reperfusion 
was more important for better outcome than it 
was for patients in the large-artery atherosclerosis-
group. We did not find stroke aetiology to be an 
independent predictor of a better 3-month mRS 
and mTICI score shift. In propensity-matched 
analysis, clinical and imaging outcome was not 
different between groups.
Table 4. Outcome according to stroke aetiology in propensity-matched analysis (matched according to demographic data, baseline 











mRS at 3 months 0.570‡
 0–1 16 (26.2%) 11 (18%) 0.278 1.62 (0.68–3.85)  
 0–2 32 (52.5%) 28 (45.9%) 0.469 1.30 (0.64–2.65)  
 0–5 (survival) 47 (77%) 48 (78.7%) 0.827 0.91 (0.39–2.14)  
 Median, range 2, 0–6 3, 0–6 0.463  
NIHSS score at discharge from acute care
 Median change, range −5, −21 to 34 −5, −21 to 37 0.925  
 Median, range 4, 0–42 7, 0–42 0.142  
Final in-hospital infarct volume 0.535 0.336‡
 <30 ml 30 (50%) 24 (40%)  
 30–90 ml 21 (35%) 26 (43.3%)  
 >90 ml 9 (15%) 10 (16.7%)  
Successful reperfusion (mTICI 
2b/3)
46 (75.4%) 40 (65.6%) 0.235 1.61 (0.73–3.54) 0.200‡
Updated Charlson Comorbidity 
Index
0.215‡
 Median, range 2, 0–12 4, 0–9 0.393  
 Subitem heart failure 20 (32.8%) 15 (24.6%) 0.318 1.50 (0.68–3.30)  
Symptomatic intracranial 
haemorrhage
5 (8.2%) 4 (6.6%) 0.730 1.27 (0.33–4.99) NA
Values are presented as number (%). Percentages indicate available data. Missing data were considered as missing, as they were incidentally 
missing.
*Denominator.
†Values compare both groups.
‡Shift over the whole spectrum of the score.
CI, confidence interval; mRS, modified Rankin scale; mTICI, modified thrombolysis in cerebral infarction; NIHSS, National Institutes of Health 
Stroke Scale; NA, not applicable.
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At present, data on whether stroke aetiology 
impacts reperfusion and outcome in endovascularly 
treated patients with acute ischaemic stroke are 
scarce.
Guglielmi and co-workers also investigated endo-
vascular therapy (±intravenous thrombolysis) in 
666 patients with cardioembolism versus large-
artery atherosclerosis.9 Patients were selected 
from the MR-CLEAN Registry. They found 
similar rates of favourable 3-month (mRS 0–2) 
outcome (35% versus 46%), mortality (33% ver-
sus 23%), successful reperfusion (56% versus 
53%) and sICH (7% versus 5%) between patients 
with cardioembolism versus large-artery athero-
sclerosis. But, the median 3-month mRS was 
lower [(3 versus 4, adjustedOR 1.45 (95% confi-
dence interval (CI) 1.03–2.05)] in patients with 
large-artery atherosclerosis. They also noted that 
patients with cardioembolism versus large-artery 












mRS at 3 months 0.580‡
 0–1 29 (24.6%) 24 (20.3%) 0.436 1.28 (0.69–2.36)  
 0–2 63 (53.4%) 57 (48.3%) 0.435 1.23 (0.74–2.04)  
 0–5 (survival) 94 (79.7%) 102 (86.4%) 0.168 0.61 (0.31–1.23)  
 Median, range 2, 0–6 3, 0–6 0.362  
NIHSS score at discharge from acute care
 Median change, range −7, −20 to 34 −6, −25 to 37 0.640  
 Median, range 4, 0–42 7, 0–42 0.076  
Final in-hospital infarct volume 0.286 0.519‡
 <30 ml 56 (48.7%) 49 (41.5%)  
 30–90 ml 40 (34.8%) 53 (44.9%)  
 >90 ml 19 (16.5%) 16 (13.6%)  
Successful reperfusion  
(mTICI 2b/3)
97 (82.2%) 88 (74.6%) 0.156 1.58 (0.84–2.95) 0.418‡
Updated Charlson Comorbidity 
Index
0.899‡
 Median, range 2, 0–16 2, 0–10 0.907  
 Subitem heart failure 31 (26.3%) 21 (17.8%) 0.118 1.65 (0.88–3.08)  
Symptomatic intracranial 
haemorrhage
3 (2.6%) 5 (4.2%) 0.491 0.60 (0.14–2.57) NA
Values are presented as number (%). Percentages indicate available data. Missing data were considered as missing, as they were incidentally 
missing.
*Denominator.
†Values compare both groups.
‡Shift over the whole spectrum of the score.
CI, confidence interval; mRS, modified Rankin scale; mTICI, modified thrombolysis in cerebral infarction; NIHSS, National Institutes of Health 
Stroke Scale.
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Table 6. Predictors of a favourable mRS and mTICI score shift and of heart failure.
Favourable mRS shift p-value
Stroke aetiology 0.922
Admission NIHSS score <0.0001
Age <0.0001
Independence (mRS 0–2) pre-stroke <0.0001





Permanent extracranial stent placement 0.580
Hypercholesterolaemia 0.680
Admission antithrombotics 0.755
Application of stent retriever 0.839
Women 0.995
Favourable mTICI score shift p-value
Stroke aetiology 0.395
Application of stent retriever <0.0001






Permanent extracranial stent placement 0.509




Admission NIHSS score 0.984
(Continued)
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atherosclerosis were older, more frequently 
female, less independent pre-stroke and showed 
more favourable treatment details. So, the main 
findings of this study are in line with those of our 
study although patients more often had lower 
3-month mRS scores in our analysis, probably 
because of higher rates of successful reperfusion. 
Successful reperfusion is crucial for a favourable 
outcome, particularly in patients with cardioem-
bolism.24,25 Also, in our analysis, successful reper-
fusion turned out to be more important for better 
outcome for patients within the cardioembolism 
group than for patients within the large-artery 
atherosclerosis group. A possible explanation for 
this finding might be that better collaterals had 
developed over the course of time in a proportion 
of patients with large-artery atherosclerosis caus-
ing a high-grade stenosis.9
Another study investigating endovascular therapy 
(±intravenous thrombolysis) in 649 Chinese 
patients with cardioembolism or large-artery 
 atherosclerosis was reported by Sun and co- 
workers.11 They found higher rates of favourable 
3-month outcome (50.2% versus 36.5%; 
p < 0.001) and survival (81.2% versus 68.2%; 
p < 0.001), and lower rates of sICH (11.7% versus 
20%; p = 0.004) in patients with large-artery ath-
erosclerosis than in those with cardioembolism 
and no significant difference in rates of successful 
reperfusion (83.2% versus 84.5%; p = 0.671). 
Large-artery atherosclerosis in Asians is more 
often in an intracranial location. This is in con-
trast to Caucasians, who more frequently suffer 
from large-artery atherosclerosis of extracranial 
brain-supplying arteries, especially if patients are 
matched for age. Therefore, direct comparability 
of this study with our analysis is limited. This is 
also true of the study by Yang and co-workers, 
who compared 45 patients in a propensity-
matched analysis.12 They too found comparable 
rates of favourable 3-month outcome, successful 
reperfusion (mTICI 2b–3) and sICH. However, 
they included only patients with occlusions of the 
M1 segment of the MCA in their analysis.
Giray and co-workers also investigated endovas-
cular therapy (±intravenous thrombolysis) in 52 
patients with cardioembolism or large-artery ath-





Independence (mRS 0–2) pre-stroke 0.027
Previous stroke 0.315
Women 0.395
Application of stent retriever 0.433
Permanent intracranial stent placement 0.571
Current smoking 0.616




Admission NIHSS score 0.912
mRS, modified Rankin scale; mTICI, modified thrombolysis in cerebral infarction; NIHSS, National Institutes of Health 
Stroke Scale.
Table 6. (Continued)
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favourable 3-month outcome (73.7% versus 
39.4%; p = 0.036) in patients with large-artery 
atherosclerosis versus cardioembolism despite 
similar rates of successful reperfusion (78% versus 
60.6%; p = 0.293) and sICH (10.5% versus 3%; 
p = 0.546). The authors suggested that longer 
delay from symptom onset to reperfusion, higher 
NIHSS score on admission, lower Alberta Stroke 
Programme Early Computed Tomography Score 
and longer procedure times with a higher median 
number of stent retriever attempts (2 versus 1; 
p = 0.02) in patients with cardioembolism proba-
bly contributed to their poorer mRS.
In our study, age and NIHSS score on admission 
were among the baseline characteristics and 
demographic data likely to worsen the outcome 
for patients with cardioembolism, which helps 
explain our findings in the univariable analysis. 
These findings are in line with historical findings 
that ischaemic stroke of cardioembolic origin is 
associated with worse outcome.7–9 However, in 
our study, most treatment details were more 
favourable in patients with cardioembolism, 
which helps explain our findings in the propen-
sity-matched analysis. Patients with cardioembo-
lism had more frequently a shorter median delay 
from groin-puncture to end of endovascular ther-
apy, less frequently received general anaesthesia, 
had a higher number of stent retriever applica-
tions, fewer stent retriever attempts and fewer 
permanent stent placements. In their study 
Guglielmi and co-workers also reported longer 
procedure times and fewer first-pass effects in 
patients with large-artery atherosclerosis.9 There 
are several reasons why endovascular therapy 
might be more challenging in patients with large-
artery atherosclerosis. First, vessel access is more 
likely to be difficult. Although a stent retriever 
improves outcome, optimal contact with the 
thrombus surface is crucial for its successful 
application. However, this contact can be limited 
in patients with large-artery atherosclerosis 
because atherosclerotic lesions can have an irreg-
ular shape.26 Furthermore, since acute large ves-
sel occlusion in large-artery atherosclerosis is 
typically caused by an underlying unstable plaque, 
there is a high risk of reocclusion by subsequent 
platelet activation and recurrent thrombus forma-
tion, which might be addressed by permanent 
extra- or intracranial stenting and administration 
of blood thinners.26 Moreover, cardioembolic 
thrombi are less likely to adhere to the site of 
vessel occlusion than in-situ thrombi, facilitating 
reperfusion.27 However, this might be true for 
arterio-arterial embolic thrombi as well. Also, car-
dioembolic thrombi tend to be more organized 
and to consist of a higher white platelet-fibrin 
fraction in comparison with the red erythrocyte-
fibrin thrombi of large-artery atherosclerosis. Less 
organized and red thrombi have been reported to 
be easier to resolve and/or retrieve.28,29
Last but not least, in our study, heart failure was 
likelier in patients with cardioembolism versus 
large-artery atherosclerosis and impacting out-
come, but not independently. Patients with heart 
failure are mostly elderly. These patients suffer 
from several diseases and experience various symp-
toms limiting daily activities and quality of life.30
Strengths and limitations
Strengths of our study are the considerable sam-
ple size and the setting of a tertiary stroke centre 
with a high level of expertise in endovascular 
therapy.
Limitations are the retrospective design, imbal-
ances of baseline variables and the inclusion of 
patients over a period of time where treatment 
has evolved. Also, it is likely that a few patients 
who did have cardioembolism or large-artery ath-
erosclerosis were excluded because of undeter-
mined stroke aetiology. Moreover, we did not 
differentiate between intracranial and extracra-
nial location of large-artery atherosclerosis. Then, 
follow-up data on a few patients were missing. 
Missing data were considered as missing, as they 
were incidentally missing. Finally, it might have 
been even more meaningful to compare cardi-
oembolism with large-artery atherosclerosis at the 
same vessel occlusion site due to the different 
pathogenesis of atherosclerotic occlusion and the 
heterogeneity of interventional protocols.
Conclusion
We suggest prospective studies to further eluci-
date differences in reperfusion and outcome in 
patients with cardioembolism versus large-artery 
atherosclerosis.
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